Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The life study

American Journal of Hypertension

Volumn 23, Issue 8, 2010, Pages 845-851

  Wiik, Benedicte P ^a   Larstorp, Anne C K ^a   Høieggen, Aud ^a   Kjeldsen, Sverre E ^a,b   Olsen, Michael Hecht ^c   Ibsen, Hans ^d   Lindholm, Lars ^e   Dahlöf, Björn ^f   Devereux, Richard B ^g   Okin, Peter M ^g   Wachtell, Kristian ^h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d HOLBÆK HOSPITAL   (Denmark)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

blood pressure; hypertension; left ventricular hypertrophy; new onset diabetes; serum uric acid

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; LOSARTAN; URIC ACID; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINALYSIS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; RISK FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 77955769088     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.89     Document Type: Article

References (17)

1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
2. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.
3. Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049.
4. Kizer JR, Hoieggen A, Alderman MH, Kjeldsen S, Dahlöf B, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm L, Nieminen M, Omvik P, Oparil S, Wedel H, Wachtell K, Snapinn S, Edelman J, Devereux R. Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The LIFE Study. J Am Coll Cardiol 2004; 43:475A.
5. Zacks E, Wachtell K, Gerdts E, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Devereux RB. Associaion of uric acid level with new-onset atrial fibrillation in treated hypertensive patients: The LIFE Study. Circulation 2005;112 (suppl II):II-459.
6. Kylin E. Studien über das hypertonie-hyperglykämie- hyperurikämiesyndrom. Zentral-blatt für Innere Medizin 1923;44:105-127.
7. Nan H, Qiao Q, Söderberg S, Pitkäniemi J, Zimmet P, Shaw J, Alberti G, Uusitalo U, Pauvaday V, Chitson P, Tuomilehto J. Serum uric acid and incident diabetes in Mauritian Indian and Creole populations. Diabetes Res Clin Pract 2008; 80: 321-327.
8. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31: 361-362.
9. Dai CY, Chuang WL, Ho CK, Ou T T, Huang JF, Hsieh MY, Yu ML. High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al. Diabetes Care 2008; 31:e67.
10. Lippi G, Targher G, Montagnana M, Salvagno GL, Guidi GC. High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al. Diabetes Care 2008; 31:e68.
11. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B; LIFE Study Investigators. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007; 50:984-990.
12. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10:705-713.
13. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32:989-997
14. Boon NA, Colledge NR, Walker BR, Hunter JAA (eds). Davidson's Principles & Practice of Medicine, 20th edn, 2006, p 1320.
15. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-447.
16. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32:1737-1742.
17. Ioachimescu AG, Brennan DM, Hoar BM, Kashyap SR, Hoogwerf BJ. Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study. Diabet Med 2007; 24:1369-1374.